Molina Healthcare denied your biologic and infusion therapy? Here is what to do next

Why Molina Healthcare denies biologic and infusion therapy

Molina Healthcare is concentrated in Medicaid managed care, with smaller marketplace and Medicare Advantage footprints. Appeal pathways depend heavily on the underlying line of business and the state Medicaid agency that contracts with Molina.

For biologic and infusion therapy specifically: Biologics such as adalimumab, infliximab, vedolizumab, ustekinumab, and rituximab are denied at prior authorization for step-therapy, missing labs, or diagnosis mismatch, and later for site of care or dose escalation. The appeal is a documentation exercise against the plan's own criteria.

What Molina Healthcare denies for biologic and infusion therapy

The biologic and infusion therapy services most often denied:

• First biologic for Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, or psoriasis
• Switch to a second biologic after the first stops working
• Dose escalation or interval shortening beyond the label
• Infusion at a hospital outpatient department instead of home or a standalone center
• Biosimilar substitution disputes

Why biologic and infusion therapy claims get denied

A typical Molina Healthcare biologic and infusion therapy denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

• Step therapy: conventional drugs (methotrexate, mesalamine, steroids) not tried or not documented
• Disease activity scores or lab markers missing from the record
• Diagnosis code does not match the labeled indication
• TB or hepatitis B screening not on file
• Plan prefers a different biologic or a biosimilar first

The Molina Healthcare appeal process

Appeal levels: Plan internal appeal, then state Medicaid fair hearing for Medicaid lines. Marketplace: internal then federal external review. Medicare Advantage: federal 5-level ladder.

Carrier timing: Medicaid filing windows are state-specific, commonly 60-120 days from the action notice. Continuation-of-benefits typically requires filing within 10 days. Marketplace: 180 days internal, 4 months external.

Biologics timing: Untreated inflammatory disease supports an expedited appeal: decision within 72 hours. Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D. External review: within 4 months of the final internal denial for ACA-covered plans (45 CFR 147.136).

What we know about Molina Healthcare: Molina appeals are most often won at the state fair-hearing stage. We preserve continuation-of-benefits where the timing permits and brief the case to the state's administrative law judge.

Common Molina Healthcare denial patterns for biologic and infusion therapy

• State Medicaid fair-hearing escalation. Molina Medicaid denials must first run through the plan's internal grievance and appeal process. After plan-level denial, the member has the right to a state Medicaid fair hearing, a separate administrative track that frequently overturns prior-auth and medical-necessity denials.
• Continuity-of-care protections. Medicaid rules generally require continuation of previously authorized services pending the outcome of a timely-filed appeal. Members who file within the state's continuation window (often 10 days from the action notice) preserve services during the appeal.
• EPSDT-based denials in pediatric cases. For Molina members under 21, federal EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) requirements broaden coverage beyond the adult benefit. Many pediatric denials reverse on appeal once the EPSDT framework is cited.

How to win your Molina Healthcare biologic and infusion therapy appeal

Strategy for biologic and infusion therapy: Get the plan's drug policy and match every criterion to a page in the chart: diagnosis, severity score, prior drugs with dates and outcomes, screening labs, prescriber specialty. Where step therapy is the reason, use the plan's exception process and, where applicable, the state step-therapy law that requires an override when the required drug was tried, is contraindicated, or is expected to be ineffective. For a switch after loss of response, document the objective loss of response. Ask for a peer-to-peer with a reviewer in the same specialty.

Filed against Molina Healthcare, that strategy rides on this procedural spine:

1. Procedural-rights anchor. Every Molina Healthcare denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
2. Criteria-disclosure demand. Molina Healthcare frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
3. Controlling-standard citation. Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).
4. Treating-provider attestation. A letter from the treating physician addressing each criterion in Molina Healthcare's own policy language. This is the single strongest evidentiary element.
5. Requested action. A specific demand to reverse the biologic and infusion therapy denial and approve the service, not a general "please reconsider."

Documents you'll need for your Molina Healthcare biologic and infusion therapy appeal

• The denial letter with the criterion or policy cited
• Specialist's notes with diagnosis and disease-activity measures
• Prior medication history with dates, doses, and outcomes
• TB, hepatitis, and other screening results
• The plan's drug policy and formulary exception form

What a biologic and infusion therapy appeal can recover

Typical recovery for biologic and infusion therapy cases runs Biologics are priced in the thousands of dollars per dose; a denied year of therapy is commonly a five-figure sum at billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

Molina Healthcare biologic and infusion therapy appeals: frequently asked questions

What Apellica does for Molina Healthcare biologic and infusion therapy appeals

We file appeals against Molina Healthcare specifically configured to its internal review process. Every biologic and infusion therapy appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Molina Healthcare appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Related Molina Healthcare guides

• Molina Healthcare surgery denials appeal guide
• Molina Healthcare mri and imaging denials appeal guide
• Molina Healthcare medication and prescription denials appeal guide
• Molina Healthcare medicare denials appeal guide

Biologic and infusion therapy guides for other carriers

• UnitedHealthcare biologic and infusion therapy appeal guide
• Aetna (CVS Health) biologic and infusion therapy appeal guide
• Cigna (Evernorth) biologic and infusion therapy appeal guide
• Anthem / BlueCross BlueShield biologic and infusion therapy appeal guide